Company · Ownership research

Jade Biosciences, Inc. JBIO

CIK 0001798749

Form 4 transactions dated Nov 1, 2023 to Nov 7, 2026, as reported to the SEC.

Insider trading Initial holdings Institutional holders

This page lists 30 of 34 rows; the complete set is available through the API.

Insider filings on file run through Jun 26, 2026.

Some filings are submitted jointly by several insiders. The SEC form does not apportion the reported figures between them, so results include every joint filer.

Insider purchases & sales

Purchased: $1.59M
Sold: $7.74M

Nov 1, 2023 – Jun 26, 2026
Available records · partial months are marked ·

202410 of 30 preview events · 34 available in 2024

Date	Insider	Activity	Trade value (USD)	% of prior holding
Jun 17, 2024	RA Capital Healthcare Fund LP · RA CAPITAL MANAGEMENT, L.P. · Kolchinsky Peter · Shah Rajeev M. · RA Capital Nexus Fund, L.P. Director · 10% owner	Purchase	$1.55M 928,110 shares bought	Unavailable Indirect holding	▾
Jun 14, 2024	Eldridge George A SEE REMARKS	Sale10b5-1 footnote	$375.45K 15,000 shares sold	74.92% sold Direct holding	▾
Jun 14, 2024	Verwijs Marinus CHIEF TECHNICAL OFFICER	Sale10b5-1 footnote	$265.00K 10,600 shares sold	100.00% sold Direct holding	▾
Jun 13, 2024	Gillies Hunter CHIEF MEDICAL OFFICER	Sale10b5-1 footnote	$147.00K 6,000 shares sold	51.72% sold Direct holding	▾
May 17, 2024	Gillies Hunter CHIEF MEDICAL OFFICER	Sale10b5-1 footnote	$84.33K 4,000 shares sold	41.66% sold Direct holding	▾
May 16, 2024	NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director	Sale10b5-1 footnote	$215.76K 10,000 shares sold	100.00% sold Direct holding	▾
May 2, 2024	Verwijs Marinus CHIEF TECHNICAL OFFICER	Sale	$41.63K 1,981 shares sold	100.00% sold Direct holding	▾
May 1, 2024	NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER · Director	Sale10b5-1 footnote	$230.95K 11,357 shares sold	Unavailable Direct holding	▾
Apr 17, 2024	Dake Benjamin T SEE REMARKS	Sale10b5-1 footnote	$153.33K 6,853 shares sold	84.15% sold Direct holding	▾
Apr 17, 2024	Gillies Hunter CHIEF MEDICAL OFFICER	Sale10b5-1 footnote	$89.52K 4,000 shares sold	55.16% sold Direct holding	▾

Showing 30 / 34 record groups in 2024. The complete set is available through the API.

Jade Biosciences, Inc. · JBIO

Follow the people behind the trades.

Log in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and reach other datasets through the Akkru API.

Download CSV
Earlier filings
Advanced screening & filtering
API & AI access

Already have an account?

＋ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account. For the year shown, this page lists 30 of 34 purchase / sale groups and 30 of 101 other groups; the totals and the monthly series cover the whole window.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP / CLI.

MCP  https://api.akkrudata.ai/mcp

akkru_insider_transactions
{"action":"list","ticker":"JBIO","transaction_code":["P","S"],"transaction_form_type":"4","page_size":20}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint: https://api.akkrudata.ai/mcp
API / MCP / CLI documentation: /documents
llms.txt: /llms.txt

Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

Non-cancelled, non-derivative purchase (P) and sale (S) rows dated inside the public window, as reported. Share totals are on today's split-adjusted basis. Includes open-market and private transactions. Data after the latest filing is not asserted complete and is not zero-filled. A grouped event shares filing, transaction date, security, code, direction, ownership bucket and source. Derivative groups also match underlying security, exercise price, exercise/expiration dates and footnote references. Reported rows are retained; P/S price lots can be grouped. Post-transaction balances are never summed.